Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

Previously-Stated Guidance Remains Unchanged

PRINCETON, N.J., April 3, 2008 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today issued the following statement in response to the announcement by Pfizer Inc that it was discontinuing its Phase 3 clinical trial of front-line treatment with Pfizer's single-agent anti-CTLA-4 antibody (tremelimumab) compared to chemotherapy in patients with advanced melanoma. Dr. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President, Product Development of Medarex, stated:

"While Pfizer's tremelimumab and Medarex's ipilimumab have a similar mechanism of action and have been considered by some as similar molecules, it is natural to attempt to draw parallels between the two molecules. However, we feel we need to make certain clarifications. First, the two antibodies are different molecules, and results from one antibody program may not be indicative of results from another program. The molecules are of different IgG antibody subclasses, administered at different doses and dosing schedules, and with different pharmacokinetic parameters.

Second, while, as previously reported, the results from the Phase 2 study under special protocol assessment did not meet the primary endpoint, the three studies in our Phase 2 program were suggestive of ipilimumab's potential for clinical anti-tumor activity based on the totality of the data and are under discussion with regulatory agencies.

Third, Medarex's ongoing ipilimumab Phase 3 program (study 024) for front- line treatment of advanced melanoma is different in design from the Pfizer trial, and at this time, it is too early to draw any clinical conclusions from the Pfizer announcement. In addition, a recent review of our ongoing 0
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The ... Found to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the ... report, the new study showed that harvesting stem cell-rich bone marrow from the hip, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... Portland, Ore. (PRWEB) , ... August 03, 2015 ... ... President of Government Programs, with accountability for overall performance of the company’s Medicare ... a key focus of Cambia’s strategy to deliver better health for members. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... leading provider of medical information, risk management and investigative services, has introduced ... direction toward focused, expert information solutions that improve business outcomes for its ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Today, in light of a,recent study released by ... April is National STD Awareness Month, Congresswoman Stephanie ... introduced a bi-partisan,resolution urging the House of Representatives ... prevention, screening and treatment of,sexually transmitted diseases (STD)., ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) today announced ... closes, it will report results for the first,quarter of ... Central Time, Healthcare Realty Trust will,hold a conference call ... Company and industry trends. Simultaneously with,the conference call, a ...
... Awardee to be named at 6th International Stem Cell Symposium Seoul, Korea ... ... SEOUL, Korea, April 22 AlphaMed Press,publisher of the peer-reviewed journal STEM ... the,International Stem Cell Symposium, will be presented on June 20, 2008 in,Seoul, ...
... But doctors want more data, and device not yet approved ... -- A new kind of drug-coated stent was better at ... large-scale U.S. study of the device, researchers report. , "This ... the Xience stent is superior to the Taxus stent, in ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... treatment of peripheral vascular disease,explains interruption of its ... p.m. PT/5:00 p.m./ET. As a result of teleconference,vendor ... as planned., Interested parties are encouraged to ...
... parent of a sick child is,emotionally and physically draining. ... a world where there is very little,control and every ... (See video from CIGNA Healthcare at:, http://media.medialink.com/WebNR.aspx?story=34951 ... Leukemia Foundation called the,"Hope Binder" helps parents manage the ...
Cached Medicine News:Health News:Tubbs Jones Introduces Resolution Encouraging STD Prevention 2Health News:Healthcare Realty Trust Announces First Quarter Earnings Release Date and Conference Call 2Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:New Drug-Coated Stent Does Well in Early Trial 2Health News:New Drug-Coated Stent Does Well in Early Trial 3
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... to dry trays to specialty vaginal & ... Health offers the widest offering in patient ... that are proven to be safe and ... surgical site infections. Cardinal Health Scrub Care ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... The Anti-HTLV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... assays. Comprehensive data from all major test ...
Medicine Products: